1 |
Biib017 (peginterferon beta-1a) |
Peginterferon beta-1a |
1件: D10483 D10483 💬 |
IFNAR1 2件: IFNAR1, IFNAR2 💬 |
Coronavirus disease - COVID-19 18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
013 1件: 13 💬 |
2 |
Device: biib017 (peginterferon beta-1a) autoinjector |
Peginterferon beta-1a |
1件: D10483 D10483 💬 |
IFNAR1 2件: IFNAR1, IFNAR2 💬 |
Coronavirus disease - COVID-19 18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
013 1件: 13 💬 |
3 |
Device: biib017 (peginterferon beta-1a) pre-filled syringe (pfs) |
Peginterferon beta-1a |
1件: D10483 D10483 💬 |
IFNAR1 2件: IFNAR1, IFNAR2 💬 |
Coronavirus disease - COVID-19 18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
013 1件: 13 💬 |